Cortexyme, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Cortexyme, Inc. | CRTX - NASDAQ |
$16.00-$18.00 | $17.00 | $20.00 | 4.4 million | 5/9/2019 |
| BofA Merrill Lynch, Credit Suisse | ||||||
Co-Manager(s): Canaccord Genuity, JMP Securities | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-04-12 Terms Added 2019-04-29 | ||||||
Cortexyme, Inc. Quote & Chart - Click for current quote - CRTX
IPO Boutique aggregates information on public companies and private companies, such as "CRTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Cortexyme, Inc. (adapted from Cortexyme, Inc. prospectus):
They are a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer's and other degenerative diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer's and other degenerative diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "CRTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.